##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 155 No. 10 (2025)

Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland

Cite this as:
Swiss Med Wkly. 2025;155:4252
Published
23.10.2025

Summary

Multiple myeloma is a malignant disease characterised by the clonal proliferation of plasma cells. Since the last update of the Swiss recommendations for the diagnosis and treatment of multiple myeloma in 2019, the therapeutic landscape has evolved significantly, with the development of new monoclonal antibodies, novel combination therapies, and the introduction of T-cell-redirecting treatments such as bispecific antibodies and CAR T-cell therapy. This article summarises the current diagnostic procedures and therapeutic recommendations in Switzerland.

References

  1. 1. Samaras, P., et al., Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly, 2019.149(1314):w20031. doi: https://doi.org/10.4414/smw.2019.20031
  2. 2. Bergsagel PL, Chesi MV. Molecular classification and risk stratification of myeloma. Hematol Oncol, 2013 Jun;31 Suppl 1(0 1):38-41. 10.1002/hon.2065
  3. 3. Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, et al. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer J. 2018 Oct;8(10):95. doi: https://doi.org/10.1038/s41408-018-0124-1
  4. 4. Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: results of the IMAJEM Study. J Clin Oncol. 2017 Sep;35(25):2911–8. doi: https://doi.org/10.1200/JCO.2017.72.2975
  5. 5. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 Jun;127(24):2955–62. doi: https://doi.org/10.1182/blood-2016-01-631200
  6. 6. Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1630–42. doi: https://doi.org/10.1016/S1470-2045(20)30525-8
  7. 7. Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022 Feb;9(2):e143–61. doi: https://doi.org/10.1016/S2352-3026(21)00283-0
  8. 8. Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al.; TEAMM Trial Management Group and Trial Investigators. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1760–72. doi: https://doi.org/10.1016/S1470-2045(19)30506-6
  9. 9. Bundesamt für Gesudheit (BAG), Eidgnössische Kommission für Impffragen (EKIF). Empfehlung zur Impfung von Personen mit malignen Erkrankungen und deren Haushaltskontakte. BAG-Bulletin. 2022;20:20-30. Internet: https://www.bag.admin.ch/bag/de/home/gesund-leben/gesundheitsfoerderung-und-praevention/impfungen-prophylaxe/richtlinien-empfehlungen-impfungen-prophylaxe.html
  10. 10. Goede JS, Baumann CK, Cathomas R, Khanna N, Lambert JF, Lehmann T, et al. Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies. Swiss Med Wkly. 2024 Sep;154(9):3559. doi: https://doi.org/10.57187/s.3559
  11. 11. Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023 Nov;4(6):440–51. doi: https://doi.org/10.1158/2643-3230.BCD-23-0049
  12. 12. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al.; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414–23. doi: https://doi.org/10.1038/sj.leu.2405062
  13. 13. Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN, et al. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. J Natl Compr Canc Netw. 2019 Jul;17(7):840–7. doi: https://doi.org/10.6004/jnccn.2018.7273
  14. 14. Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019 Nov;94(11):1176–84. doi: https://doi.org/10.1002/ajh.25603
  15. 15. Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, et al.; Bone Working Group of the International Myeloma Working Group. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021 Mar;22(3):e119–30. doi: https://doi.org/10.1016/S1470-2045(20)30559-3
  16. 16. Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018 Mar;19(3):370–81. doi: https://doi.org/10.1016/S1470-2045(18)30072-X
  17. 17. Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al.; DETERMINATION Investigators. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 Jul;387(2):132–47. doi: https://doi.org/10.1056/NEJMoa2204925
  18. 18. Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al.; PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Jan;390(4):301–13. doi: https://doi.org/10.1056/NEJMoa2312054
  19. 19. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct;10(10):e825–37. doi: https://doi.org/10.1016/S2352-3026(23)00217-X
  20. 20. Leypoldt LB, Tichy D, Besemer B, Hänel M, Raab MS, Mann C, et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2024 Jan;42(1):26–37. doi: https://doi.org/10.1200/JCO.23.01696
  21. 21. Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al.; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022 Nov;9(11):e810–21. doi: https://doi.org/10.1016/S2352-3026(22)00263-0
  22. 22. Broijl A. Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients: Results of the phase III randomized EMN24 Iskia trial. EMN; 2024.
  23. 23. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996 Jul;335(2):91–7. doi: https://doi.org/10.1056/NEJM199607113350204
  24. 24. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, et al.; International Myeloma Working Group. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun;117(23):6063–73. doi: https://doi.org/10.1182/blood-2011-02-297325
  25. 25. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 Aug;136(8):936–45. doi: https://doi.org/10.1182/blood.2020005288
  26. 26. Samaras P, Pfrommer S, Seifert B, Petrausch U, Mischo A, Schmidt A, et al. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma. Biol Blood Marrow Transplant. 2015 Jan;21(1):74–80. doi: https://doi.org/10.1016/j.bbmt.2014.09.020
  27. 27. Samaras P, Rütti MF, Seifert B, Bachmann H, Schanz U, Eisenring M, et al. Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study. Biol Blood Marrow Transplant. 2018 Apr;24(4):694–9. doi: https://doi.org/10.1016/j.bbmt.2017.12.775
  28. 28. Mueller BU, Keller S, Seipel K, Mansouri Taleghani B, Rauch D, Betticher D, et al. Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity. Leuk Lymphoma. 2016 May;57(5):1122–9. doi: https://doi.org/10.3109/10428194.2015.1079315
  29. 29. Jeker B, Farag S, Taleghani BM, Novak U, Mueller BU, Li Q, et al. A randomized evaluation of vinorelbine versus gemcitabine chemotherapy mobilization of stem cells in myeloma patients. Bone Marrow Transplant. 2020 Oct;55(10):2047–51. doi: https://doi.org/10.1038/s41409-020-0875-8
  30. 30. Chhabra, S., et al., Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther, 2023. 29(3): p. 174 e1-174 e10.
  31. 31. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al.; IFM 2009 Study. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017 Apr;376(14):1311–20. doi: https://doi.org/10.1056/NEJMoa1611750
  32. 32. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019 Jul;394(10192):29–38. doi: https://doi.org/10.1016/S0140-6736(19)31240-1
  33. 33. Gay F, Roeloffzen W, Dimopoulos MA, Rosiñol L, van der Klift M, Mina R, et al. Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients. Blood. 2023;142 Supplement 1:4. doi: https://doi.org/10.1182/blood-2023-177546
  34. 34. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020 Jun;7(6):e456–68. doi: https://doi.org/10.1016/S2352-3026(20)30099-5
  35. 35. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol. 2019 Mar;37(7):589–97. doi: https://doi.org/10.1200/JCO.18.00685
  36. 36. Parameswaran H, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol. 2020;38(15 _suppl.).
  37. 37. McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017 Oct;35(29):3279–89. doi: https://doi.org/10.1200/JCO.2017.72.6679
  38. 38. Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al.; Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024 Aug;25(8):1003–14. doi: https://doi.org/10.1016/S1470-2045(24)00282-1
  39. 39. Badros A, Foster L, Anderson LD Jr, Chaulagain CP, Pettijohn E, Cowan AJ, et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025 Jan;145(3):300–10. doi: https://doi.org/10.1182/blood.2024025746
  40. 40. Sonneveld, P., et al., Daratumumab + bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma: analysis of minimal residual disease in the PERSEUS trial. EHA Library 2024, Abstract S201.
  41. 41. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012 Aug;30(24):2946–55. doi: https://doi.org/10.1200/JCO.2011.39.6820
  42. 42. Panopoulou A, Cairns DA, Holroyd A, Nichols I, Cray N, Pawlyn C, et al. Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. 2023 Apr;141(14):1666–74. doi: https://doi.org/10.1182/blood.2022018339
  43. 43. Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, et al. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2020 Jun;38(17):1928–37. doi: https://doi.org/10.1200/JCO.19.02515
  44. 44. Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021 Dec;22(12):1705–20. doi: https://doi.org/10.1016/S1470-2045(21)00535-0
  45. 45. Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 Feb;24(2):139–50. doi: https://doi.org/10.1016/S1470-2045(22)00738-0
  46. 46. Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020 Nov;20(1):1087. doi: https://doi.org/10.1186/s12885-020-07503-y
  47. 47. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al.; MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019 May;380(22):2104–15. doi: https://doi.org/10.1056/NEJMoa1817249
  48. 48. Facon, T., Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnose multiple myeloma: MAIA study. EHA 2024, Abstract P968.
  49. 49. Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 Feb;389(10068):519–27. doi: https://doi.org/10.1016/S0140-6736(16)31594-X
  50. 50. Durie BG, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020 May;10(5):53. doi: https://doi.org/10.1038/s41408-020-0311-8
  51. 51. O’Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 Jul;182(2):222–30. doi: https://doi.org/10.1111/bjh.15261
  52. 52. Mateos MV, San-Miguel J, Cavo M, Bladé Creixenti J, Suzuki K, Jakubowiak A, et al. Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study. Blood. 2022;140 Supplement 1:10157–9. doi: https://doi.org/10.1182/blood-2022-163347
  53. 53. Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, et al. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J Clin Oncol. 2021 Jan;39(3):227–37. doi: https://doi.org/10.1200/JCO.20.01370
  54. 54. Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, et al.; IMROZ Study Group. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Oct;391(17):1597–609. doi: https://doi.org/10.1056/NEJMoa2400712
  55. 55. Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024 Aug;30(8):2235–41. doi: https://doi.org/10.1038/s41591-024-03050-2
  56. 56. Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025 Apr;31(4):1195–202. doi: https://doi.org/10.1038/s41591-024-03485-7
  57. 57. Larocca A, Bonello F, Gaidano G, D’Agostino M, Offidani M, Cascavilla N, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021 Jun;137(22):3027–36. doi: https://doi.org/10.1182/blood.2020009507
  58. 58. Manier S, Corre J, Hulin C, Laribi K, Araujo C, Pica GM, et al. A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial. Blood. 2022;140 Supplement 1:1369–70. doi: https://doi.org/10.1182/blood-2022-159933
  59. 59. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al.; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May;117(18):4691–5. doi: https://doi.org/10.1182/blood-2010-10-299487
  60. 60. Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 Dec;4(23):5988–99. doi: https://doi.org/10.1182/bloodadvances.2020002827
  61. 61. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar;41(8):1590–9. doi: https://doi.org/10.1200/JCO.22.00940
  62. 62. Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar;41(8):1600–9. doi: https://doi.org/10.1200/JCO.21.02734
  63. 63. Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509–18. doi: https://doi.org/10.1016/j.clml.2019.09.623
  64. 64. Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 Jan;23(1):65–76. doi: https://doi.org/10.1016/S1470-2045(21)00579-9
  65. 65. Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 May;13(1):72. doi: https://doi.org/10.1038/s41408-023-00797-8
  66. 66. Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018 Jul;19(7):953–64. doi: https://doi.org/10.1016/S1470-2045(18)30354-1
  67. 67. Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al.; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801–12. doi: https://doi.org/10.1016/S1470-2045(21)00128-5
  68. 68. Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416–27. doi: https://doi.org/10.1016/S1470-2045(22)00019-5
  69. 69. Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, et al. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018 Apr;11(1):49. doi: https://doi.org/10.1186/s13045-018-0583-7
  70. 70. Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018 Nov;379(19):1811–22. doi: https://doi.org/10.1056/NEJMoa1805762
  71. 71. Dimopoulos M, Weisel K, Moreau P, Anderson LD Jr, White D, San-Miguel J, et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia. 2021 Jun;35(6):1722–31. doi: https://doi.org/10.1038/s41375-020-01021-3
  72. 72. Garderet L, Kuhnowski F, Berge B, Roussel M, Devlamynck L, Petillon MO, et al. Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma. Br J Haematol. 2023 Jun;201(6):1103–15. doi: https://doi.org/10.1111/bjh.18772
  73. 73. Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, et al.; German Myeloma Multicenter Group (GMMG). Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2021 Apr;35(4):1134–44. doi: https://doi.org/10.1038/s41375-020-0948-0
  74. 74. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep;29(9):2259–67. doi: https://doi.org/10.1038/s41591-023-02528-9
  75. 75. Moreau P, Garfall AL, van de Donk NW, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 Aug;387(6):495–505. doi: https://doi.org/10.1056/NEJMoa2203478
  76. 76. Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NW, Rodríguez-Otero P, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec;387(24):2232–44. doi: https://doi.org/10.1056/NEJMoa2204591
  77. 77. Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar;388(11):1002–14. doi: https://doi.org/10.1056/NEJMoa2213614
  78. 78. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 Jul;398(10297):314–24. doi: https://doi.org/10.1016/S0140-6736(21)00933-8
  79. 79. San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul;389(4):335–47. doi: https://doi.org/10.1056/NEJMoa2303379
  80. 80. Mateos MV. Overall Survival With Ciltacabtagene Autoleucel Versus Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Study Update. IMS; 2024.
  81. 81. Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NW, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023 Jan;141(3):219–30. doi: https://doi.org/10.1182/blood.2022015526
  82. 82. Nooka A, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies. J Clin Oncol. 2023;41(16 _suppl.).
  83. 83. Ferreri CJ, Hildebrandt MA, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 Aug;13(1):117. doi: https://doi.org/10.1038/s41408-023-00886-8
  84. 84. Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, et al. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). J Clin Oncol. 2021 Nov;39(32):3602–12. doi: https://doi.org/10.1200/JCO.21.00443
  85. 85. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 Aug;381(8):727–38. doi: https://doi.org/10.1056/NEJMoa1903455
  86. 86. Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020 Nov;396(10262):1563–73. doi: https://doi.org/10.1016/S0140-6736(20)32292-3
  87. 87. Leong S, Lam HP, Kirkham Z, Popat R. Antibody drug conjugates for the treatment of multiple myeloma. Am J Hematol. 2023 Mar;98(S2 Suppl 2):S22–34. doi: https://doi.org/10.1002/ajh.26750
  88. 88. Dimopoulos MA, Hungria VT, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10):e801–12. doi: https://doi.org/10.1016/S2352-3026(23)00243-0
  89. 89. Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al.; DREAMM-7 Investigators. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug;391(5):393–407. doi: https://doi.org/10.1056/NEJMoa2405090
  90. 90. Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al.; DREAMM-8 Investigators. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N Engl J Med. 2024 Aug;391(5):408–21. doi: https://doi.org/10.1056/NEJMoa2403407